<DOC>
	<DOCNO>NCT02774902</DOCNO>
	<brief_summary>The purpose study evaluate effect multiple oral dos clarithromycin pharmacokinetics TAK-438 metabolite healthy male adult participant follow single oral dose TAK-438 .</brief_summary>
	<brief_title>TAK-438_110 Drug Interaction With Cytochrome P450 3A4 ( CYP3A4 ) Inhibitor Clarithromycin</brief_title>
	<detailed_description>The drug test study call TAK-438 . TAK 438 test assess effect multiple oral dos clarithromycin pharmacokinetics TAK-438 . The study enroll approximately 16 healthy adult male participant non-Japanese origin . Participants assign : - TAK-438 40 mg - Clarithromycin 500 mg All participant ask take 2 tablet TAK-438 20 mg orally , Days 1 8 along Clarithromycin 500 mg , tablet , orally twice daily Days 3 9 . This single center trial conduct Europe . The overall time participate study maximum 44 day . Participants confine site 10 day , final visit 4 day discharge unit follow-up assessment .</detailed_description>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>1 . In opinion investigator participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Is healthy adult male participant , nonJapanese origin . 4 . Is age 18 45 year , inclusive , time informed consent first study medication dose . 5 . Weighs least 45 kg body mass index ( BMI ) 18 30 kg/m^2 , inclusive Screening . 6 . A male participant sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 12 week last dose . 7 . Has clinical laboratory evaluation ( include clinical chemistry , hematology , urinalysis ) , within reference range test laboratory . Participants evaluation outside reference range deem clinically significant investigator may include investigator discretion unless specifically identify exclusion criterion . 8 . Is willing abstain caffeine alcohol 72 hour first dose ( Day 1 ) Followup call . 9 . Is willing abstain strenuous exercise 72 hour first dose ( Day 1 ) Followup call . 10 . Is willing provide sample pharmacogenomic analysis . 1 . Has receive investigational compound within 90 day prior first dose Day 1 . 2 . Has receive TAK438 previous clinical study therapeutic agent . 3 . Is immediate family member , study site employee , dependant relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress . 4 . Has know hypersensitivity allergy clarithromycin associate excipients . 5 . Has history drug abuse ( define illicit drug use ) history alcohol abuse within 5 year prior Screening Visit unwilling agree abstain alcohol drug throughout study . 6 . Has take require take excluded medication . 7 . Intends donate sperm course study 12 week thereafter . 8 . Has evidence current cardiovascular , central nervous system , hepatic , hematopoietic disease , renal dysfunction , metabolic endocrine dysfunction , serious allergy , asthma hypoxemia , hypertension , seizure , allergic skin rash . There find participant 's medical history , physical examination , safety laboratory test give reasonable suspicion disease would contraindicate take TAK438 , similar drug class , clarithromycin , might interfere conduct study . This include , limited , peptic ulcer disease , seizure disorder , cardiac arrhythmia . 9 . Has history clinical manifestation significant symptomatic , gastroesophageal reflux disease ( GERD ) , erosive esophagitis ( EE ) , duodenal ulcer , gastric ulcer , dyspepsia , Barrett esophagus ( BE ) , ZollingerEllison syndrome . 10 . Has current recent ( within 6 month ) gastrointestinal disease would expect influence absorption drug ( ie , history malabsorption , esophageal reflux , peptic ulcer disease , EE frequent [ per week ] , occurrence heartburn , surgical intervention [ eg , cholecystectomy ] ) . 11 . Has history cancer , except basal cell carcinoma remission least 5 year prior Day 1 . 12 . Has positive test result hepatitis A , hepatitis B surface antigen , antibody hepatitis C virus , human immunodeficiency virus Screening . 13 . Has use nicotinecontaining product ( include limit cigarette , pipe , cigar , chew tobacco , nicotine patch nicotine gum ) within 6 week prior Checkin Day 1 . Urine test positive Screening Checkin ( Day 1 ) . 14 . Has positive alcohol breath test Screening Checkin ( Day 1 ) . 15 . Has confirm positive result drug abuse Screening Visit Checkin ( Day 1 ) . 16 . Has abnormal Screening Day 1 laboratory value suggest clinically significant underlying disease participant follow laboratory abnormality : alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level exceed 3*upper limit normal ( ULN ) set test laboratory Screening Visit Checkin ( Day 1 ) . 17 . Has poor peripheral venous access . 18 . Has donate lose 450 mL blood volume ( include plasmapheresis ) , transfusion blood product within 90 day prior Day 1 . 19 . Is unable understand verbal write English language certify translation inform consent material supply completion participant available . 20 . Has Screening Checkin ( Day 1 ) abnormal ( clinically significant ) electrocardiogram ( ECG ) . Entry participant abnormal ( clinically significant ) ECG must approve , document signature principal investigator . 21 . Has mark baseline prolongation QT/QTc interval ( eg , repeated demonstration QTc interval &gt; 450 m ) ECG Screening Visit . 22 . Has history clinically significant inflammatory disease allergy ( eg , hay fever [ hay fever sufferer require medication may permit ] , asthma , eczema ) , autoimmune disease ( eg , psoriasis , lupus ) , history chronic respiratory disease ( eg , emphysema chronic obstructive pulmonary disease ) . 23 . Has history additional risk factor torsades de pointes ( eg , heart failure , hypokalemia , family history Long QT Syndrome ) . 24 . Is consider investigator , reason , unsuitable candidate participate study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>